Literature DB >> 19029966

Palifermin dose should be adjusted to different therapy regimens.

M P M Verhagen, M J Wondergem, O Visser.   

Abstract

Mesh:

Substances:

Year:  2008        PMID: 19029966     DOI: 10.1038/bmt.2008.378

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  3 in total

Review 1.  Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients.

Authors:  Judith E Raber-Durlacher; Inger von Bültzingslöwen; Richard M Logan; Joanne Bowen; Abdul Rahman Al-Azri; Hele Everaus; Erich Gerber; Jesùs Garcia Gomez; Bo G Pettersson; Yoshihiko Soga; Fred K L Spijkervet; Wim J E Tissing; Joel B Epstein; Sharon Elad; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2012-09-18       Impact factor: 3.603

2.  Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines.

Authors:  Richard M Logan; Abdul Rahman Al-Azri; Paolo Bossi; Andrea M Stringer; Jamie K Joy; Yoshihiko Soga; Vinisha Ranna; Anusha Vaddi; Judith E Raber-Durlacher; Rajesh V Lalla; Karis Kin Fong Cheng; Sharon Elad
Journal:  Support Care Cancer       Date:  2020-02-21       Impact factor: 3.603

Review 3.  Efficacy of palifermin in the hematopoietic stem cell transplant setting.

Authors:  Muneera Panjwani
Journal:  J Adv Pract Oncol       Date:  2013-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.